Tagged Articles

type 2 80 articles

Type 2 diabetes drug Actos now available in generic versions

The type 2 diabetes drug Actos (pioglitazone) is now available as a lower-costing generic. Actos is marketed by Japanese drug maker Takeda Pharmaceuticals. The patent for Actos expires in 2016; however, under the terms of a 2010 legal settlement, generic versions can be marketed as early as August 17, 2012. Both Ranbaxy Laboratories and Teva Pharmaceuticals are now selling generic Actos in three different doses. Another generic drug company, Watson Pharmaceuticals, had hoped to launch a generic version of Actos this week, but the Food and Drug Administration (FDA) has yet to grant the drug final approval. Last week, Watson ... Read More

Drug company sues FDA to gain approval for generic Actos

Watson Pharmaceuticals is suing the Food and Drug Administration (FDA) in order to gain approval for its generic version of the type 2 diabetes drug Actos (pioglitazone). Actos is marketed by Japanese drug maker Takeda Pharmaceuticals. The patent for Actos expires in 2016; however, under the terms of a 2010 legal settlement between Takeda and Watson, Takeda licensed the U.S. patents to Watson and allowed it to start marketing a generic version of the drug beginning August 17, 2012. This shared marketing exclusivity would keep most other generic versions of Actos off the market for 180 days. However, the FDA ... Read More

15 million American diabetics at risk for bladder cancer

Fifteen million Americans who take a class of drugs to treat type 2 diabetes are at risk for developing bladder cancer, according to a new study published this month in the Journal of the National Cancer Institute. As much as 20 percent of the drugs prescribed to diabetics in the United States are thiazolidinediones, or TZDs. Drugs in this class include Avandia (rosiglitazone), Actos (pioglitazone) and Rezulin (troglitazone). In 2008, the Food and Drug Administration (FDA) withdrew Rezulin from the market due to an increased incidence of drug-induced hepatitis. In 2010, the FDA severely restricted the use of Avandia after ... Read More

Actos may be tested as treatment for Alzheimer’s disease

The type 2 diabetes drug Actos, which was recently linked to bladder cancer, may soon be tested on people with Alzheimer’s disease to see if it can help with memory retention. Researchers at the University of Virginia Health System and Case Western Reserve University say that drugs used to keep high blood sugar in check may also help slow memory loss. With this in mind, researchers focused on the drug Actos (pioglitazone). “We believe that the drug may reduce the body’s inflammatory reaction to one of the toxic components that builds up in Alzheimer’s, called amyloid plaque,” says Dr. David ... Read More

Normal weight type 2 diabetics more likely to die from disease than overweight, obese diabetics

Normal-weight people with type 2 diabetes are twice as likely to die from the disease than overweight or obese people with type 2 diabetes, according to a new study recently published in the Journal of the American Medical Association. The study compared death rates among 2,625 type 2 diabetics aged 40 and older, and found that the death rate among normal-weight diabetics was 284.8 per 10,000 person-years compared to 152.1 per 10,000 person-years in overweight or obese diabetics. They also found that older adults and non-white participants were more likely to develop type 2 diabetes at a normal weight. Researchers ... Read More

Paula Deen’s diabetes drug of choice brings in hearty profits

Danish pharmaceutical company Novo Nordisk is rolling in profits, thanks to strong sales of its new diabetes drugs. Novo Nordisk is the world’s largest insulin manufacturer. It also makes non-insulin medications to treat type 2 diabetes including Victoza, a new treatment that is being promoted by Southern celebrity cookbook author Paula Deen. Deen caught a lot of flack when she announced earlier this year that she had been diagnosed three years ago with type 2 diabetes. Deen’s Southern-fried and sugar-filled recipes are prime examples of the kinds of foods that contribute to the country’s growing obesity and diabetes epidemic. But ... Read More

Pumping iron reduces men’s risk for developing type 2 diabetes

Men who pump iron are less likely to develop type 2 diabetes, according to a new study published in a recent issue of the Archives of Internal Medicine. For the study, researchers from Harvard University and the University of Southern Denmark followed 32,000 men from 1990 until 2008. They studied the role exercise and weight training had on their risk for diabetes, a condition that affects nearly 350 million people worldwide. About 2,275 people developed diabetes during the study period. After adjusting for factors such as television viewing habits, family history, smoking, and diet, researchers categorized the men into three ... Read More

GSK to apply for FDA approval for new type 2 diabetes drug

Final data on clinical trials for GlaxoSmithKline’s experimental type 2 diabetes drug Albiglutide are promising enough that the drug company will seek Food and Drug Administration (FDA) approval early next year. Albiglutide is a once-weekly treatment that belongs to a class of injectable GLP-1 medicines. Others in the class include Byetta, made by Amylin Pharmaceuticals and Eli Lilly, and Novo Nordisk’s Victoza, now promoted by celebrity chef Paula Deen. Albiglutide’s path to FDA approval has been rocky. Last November, the first of a series of late-stage clinical trials on the drug showed that it did not cut blood sugar levels ... Read More

Takeda resubmits application for diabetes drug with cancer risk

Japanese drug maker Takeda Pharmaceutical is hoping to win Food and Drug Administration (FDA) approval for two diabetes drugs despite a highly publicized cancer risk with one of the drugs. Takeda announced that it is resubmitting its application for alogliptin and a drug that combines alogliptin with pioglitazone, the active ingredient in Takeda’s type 2 diabetes drug Actos. Takeda has been seeking FDA approval for alogliptin since 2009, when it was originally rejected because there was not enough information about potential cardiovascular risk. Takeda resubmitted its application only to have it rejected last May because the FDA wanted more information about ... Read More

Deen’s partnership with diabetes drug adds more weight to her bank account

Celebrity chef Paula Deen caught a lot of flack when she announced earlier this year that she had been diagnosed three years prior with type 2 diabetes. Deen is known for her fried and sugar-filled recipes, the same types of foods that contribute to the country’s growing obesity and diabetes epidemic. She caught heat in the media for being a hypocrite, and one would assume that such bad press would hurt one’s earnings. But Forbes magazine says “her diversified food business couldn’t be more healthy.” In fact, her earnings this past year reached an estimated $17 million, making her the ... Read More